Roche TecentriqBeyond's analysis on Roche Tecentriq2026-10-09 — FDA’s approval of Roche’s Tecentriq for adjuvant colon cancer expands immunotherapy options and promises a new revenue stream for the drugRecent news mentioning Roche Tecentriq2026-10-09 — FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancerAppears alongsideFDAIIIBrowse the full archive →